William Blair analyst Lachlan Hanbury Brown has reiterated their bullish stance on SPRY stock, giving a Buy rating on March 7.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors including ARS Pharmaceuticals’ strong initial market performance and strategic advancements. The company reported net product revenues for neffy that slightly exceeded expectations, indicating a positive market reception. Additionally, ARS has made notable progress in engaging healthcare professionals, with a significant number having already prescribed neffy, and has received positive feedback from its neffy experience program.
Furthermore, ARS Pharmaceuticals has achieved significant milestones in securing insurance coverage, with favorable decisions from major plans like Express Scripts and Cigna Healthcare. The company is on track to achieve substantial commercial coverage earlier than previously anticipated, which is crucial for driving future sales. These strategic moves and positive market indicators underpin Lachlan Hanbury Brown’s confidence in recommending a Buy rating for ARS Pharmaceuticals.
In another report released on March 7, Scotiabank also initiated coverage with a Buy rating on the stock with a $30.00 price target.